146 related articles for article (PubMed ID: 38187183)
1. Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy.
Yoshimura A; Yamamoto Y; Nishikawa T; Fujita M; Inoue T; Kondo F; Hayashi T; Kawamura N; Nagahara A; Nakai Y; Nakayama M; Nishimura K
Int Cancer Conf J; 2024 Jan; 13(1):26-32. PubMed ID: 38187183
[TBL] [Abstract][Full Text] [Related]
2. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
[TBL] [Abstract][Full Text] [Related]
3. Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib.
Airò G; Maffezzoli M; Lazzarin A; Bianconcini M; Greco A; Buti S; Leonetti A
Immunotherapy; 2022 Nov; 14(16):1297-1305. PubMed ID: 36408614
[TBL] [Abstract][Full Text] [Related]
4. Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib.
Nishimoto K; Shirotake S; Miyama Y; Kaneko G; Kanao K; Igarashi D; Takahashi T; Umezawa Y; Yasuda M; Oyama M
IJU Case Rep; 2022 May; 5(3):149-152. PubMed ID: 35509782
[TBL] [Abstract][Full Text] [Related]
5. Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome.
Urasaki T; Ono M; Mochizuki T; Takeda K; Nishizawa A; Fukagawa E; Fujiwara M; Komai Y; Kitano S; Yuasa T; Yonese J; Takahashi S
Front Oncol; 2021; 11():681997. PubMed ID: 33996612
[TBL] [Abstract][Full Text] [Related]
6. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
7. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
Stellato M; Buti S; Maruzzo M; Bersanelli M; Pierantoni F; De Giorgi U; Di Napoli M; Iacovelli R; Vitale MG; Ermacora P; Malgeri A; Maiorano BA; Prati V; Mennitto A; Cavo A; Santoni M; Carella C; Fratino L; Procopio G; Verzoni E; Santini D
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674615
[TBL] [Abstract][Full Text] [Related]
9. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
[TBL] [Abstract][Full Text] [Related]
10. Cytokine Release Syndrome More than Two Years after Pembrolizumab Introduction: A Case Report.
Nakashima K; Kitani K; Kono K; Yoshihara K; Kawakado K; Kobayashi M; Okuno T; Amano Y; Tsubata Y; Isobe T
Intern Med; 2023 Dec; ():. PubMed ID: 38104995
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint inhibitor-induced gastritis followed by delayed severe hepatitis in a patient with lung metastases of head and neck squamous cell carcinoma: a case report.
Otsuka T; Hashii Y; Murayama S; Ishizuka Y; Kojitani Y; Nishio M; Kudo T
Front Oncol; 2023; 13():1164236. PubMed ID: 37251947
[TBL] [Abstract][Full Text] [Related]
12. Immune-related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis.
Imai S; Nakamura M; Chujo S; Ooki R; Inoue Y; Horiuchi H; Morikawa T; Uchino K; Igarashi A; Shiga Y
IJU Case Rep; 2021 Nov; 4(6):386-390. PubMed ID: 34755064
[TBL] [Abstract][Full Text] [Related]
13. [COMPLETE REMISSION OF METASTATIC RENAL CELL CARCINOMA AFTER PARTIAL NEPHRECTOMY FOLLOWING PEMBROLIZUMAB PLUS AXITINIB THERAPY: A CASE REPORT].
Hakamata Y; Uchida K; Noda T; Imai S; Yoneda T; Kudoh S
Nihon Hinyokika Gakkai Zasshi; 2022; 113(4):139-142. PubMed ID: 37866934
[TBL] [Abstract][Full Text] [Related]
14. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report.
Katsumata Y; Kawasaki Y; Tanaka K; Nakayama D; Katayama H; Shimada S; Satake Y; Sato T; Kawamorita N; Yamashita S; Sato T; Shoji K; Mitsuzuka K; Ito A
Case Rep Oncol; 2021; 14(3):1522-1529. PubMed ID: 34899246
[TBL] [Abstract][Full Text] [Related]
16. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
17. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
18. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Rini BI; Atkins MB; Plimack ER; Soulières D; McDermott RS; Bedke J; Tartas S; Alekseev B; Melichar B; Shparyk Y; Kondoh C; Langiewicz P; Wood LA; Hammers H; Silber CG; Haber B; Jensen E; Chen M; Powles T
Eur Urol Oncol; 2022 Apr; 5(2):225-234. PubMed ID: 34244116
[TBL] [Abstract][Full Text] [Related]
19. Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report.
Hanawa K; Sawada N; Aikawa J; Otake Y; Kasai Y; Mochizuki K; Shimura H; Mochizuki T; Kira S; Mitsui T
Oncol Lett; 2024 Feb; 27(2):66. PubMed ID: 38192652
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
